Saturday - December 13, 2025
GSK's RSV Vaccine, Arexvy, Receives Positive CHMP Opinion for All Adults 18 Years and Older
December 12, 2025
LONDON, England, Dec. 12 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:

* * *

GSK's RSV vaccine, Arexvy, receives positive CHMP opinion for all adults 18 years and older

- Marketing authorisation expected in February 2026

- Every year an average of 158,000 adults are hospitalised with RSV-related illness in the EU/1

*

GSK plc (LSE/NYSE: GSK) today announced that . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products